RANCHO CORDOVA, Calif.,
Nov. 5, 2020 /PRNewswire/
-- ThermoGenesis Holdings, Inc. (Nasdaq: THMO), a market
leader in automated cell processing tools and services in the cell
and gene therapy field, today announced that the
Company will release its financial results for the third quarter
ended September 30, 2020 and provide
a corporate strategic update on Thursday,
November 12, 2020 after the close of trading. A conference
call and webcast will follow at 1:30 p.m.
PT/ 4:30 p.m. ET.
To participate in the conference call, please dial
1-844-889-4331 (domestic), 1-412-380-7406 (international)
or 1-866-605-3852 (Canada).
To access a live webcast of the call, please
A webcast replay will be available on ThermoGenesis' website for
three months by visiting the Investor page of the Company's website
About ThermoGenesis Holdings, Inc.
Holdings, Inc. develops, commercializes, and markets a range of
automated technologies for CAR-T and other cell-based therapies.
The Company currently markets a full suite of solutions for
automated clinical biobanking, point-of-care applications, and
automation for immuno-oncology, including its semi-automated,
functionally-closed CAR-TXpress™ platform, which streamlines
the manufacturing process for the emerging CAR-T immunotherapy
market. For more information about ThermoGenesis, please
Paula Schwartz, Rx
SOURCE ThermoGenesis Holdings, Inc.